Company profile: Beam Therapeutics
1.1 - Company Overview
Company description
- Provider of precision genetic medicines using base editing, including BEAM-101 for sickle cell disease; BEAM-201, an anti-CD7 CAR-T for relapsed/refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma; and liver-targeting LNPs BEAM-301 and BEAM-302 to correct the R83C mutation in Glycogen Storage Disease Type 1a and the PiZ allele in severe Alpha-1 antitrypsin deficiency, plus base editing delivery technologies.
Products and services
- Base Editing Applications: A clinically validated suite of technologies that delivers precision genetic medicines using electroporation as well as nonviral and viral delivery modalities for therapeutic base editing
- BEAM-101: An investigational base-editing therapy for sickle cell disease that mimics genetic variants found in individuals with hereditary persistence of fetal hemoglobin to emulate HPFH biology
- BEAM-201: A multiplex base-edited anti-CD7 CAR-T cell therapy engineered for relapsed and refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Beam Therapeutics
Regulus Therapeutics
HQ: United States
Website
- Description: Provider of microRNA-based therapeutics designed to inhibit dysregulated microRNA targets for genetically based orphan diseases, particularly orphan kidney diseases. Portfolio includes RGLS8429, a next-generation anti-miR-17 in Phase 1b for autosomal dominant polycystic kidney disease (ADPKD), supported by ongoing clinical trials to evaluate efficacy and safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Regulus Therapeutics company profile →
Rocket Pharmaceuticals
HQ: United States
Website
- Description: Provider of gene therapies for rare childhood disorders, developing lentiviral and AAV vector-based programs including RP-L102 for Fanconi Anemia, RP-L301 for Pyruvate Kinase Deficiency, an AAV program for Danon Disease, and gene therapies for LAD-I, PKP2 arrhythmogenic cardiomyopathy, and BAG3-associated dilated cardiomyopathy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rocket Pharmaceuticals company profile →
Akouos
HQ: United States
Website
- Description: Provider of AAV vector-based gene therapies to restore and preserve hearing in genetically defined patient populations, addressing causes from single gene mutations to ototoxic drug exposure and aging. Offers AK-OTOF, a gene therapy targeting sensorineural hearing loss due to otoferlin mutations, and the Resonate Program, no-cost genetic testing with optional counseling for auditory neuropathy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akouos company profile →
EG 427
HQ: France
Website
- Description: Provider of pinpoint gene therapy using non-replicative HSV-1 vectors. Offers EG110A for neurogenic bladder dysfunction and overactive bladder; a platform delivering large genes with precise control and long-term expression for peripheral nervous system disorders; vector engineering with specific promoters for targeted sensory or autonomic neuronal subsets; and R&D expanding to chronic indications, including central nervous system neurons.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EG 427 company profile →
Sarepta Therapeutics
HQ: United States
Website
- Description: Provider of precision genetic medicines for rare diseases, including gene therapies for Duchenne muscular dystrophy, limb-girdle muscular dystrophy, and Charcot-Marie-Tooth disease; RNA-targeted exon-skipping therapies for Duchenne muscular dystrophy using PMO and PPMO chemistries; and SareptAssist, a U.S. patient support program for initiating and maintaining therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sarepta Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Beam Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Beam Therapeutics
2.2 - Growth funds investing in similar companies to Beam Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Beam Therapeutics
4.2 - Public trading comparable groups for Beam Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →